Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 9/20 | 0.61 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087794 | 1.00 | NAAA (0.61) | NAAAASAH1ALDH1A1KDM4EEPHX1 | |
| SCHEMBL10719082 | 1.00 | NAAA (0.61) | NAAAASAH1ALDH1A1KDM4EEPHX1 | |
| SCHEMBL4078569 | 0.96 | NAAA (0.62) | NAAAASAH1ALDH1A1CTSLGAA | |
| SCHEMBL4077967 | 0.96 | NAAA (0.62) | NAAAASAH1ALDH1A1CTSLGAA | |
| SCHEMBL4077965 | 0.96 | NAAA (0.62) | NAAAASAH1ALDH1A1CTSLGAA | |
| SCHEMBL6200442 | 0.92 | NAAA (0.57) | NAAAASAH1ALDH1A1EPHX1 | |
| SCHEMBL6200454 | 0.92 | NAAA (0.57) | NAAAASAH1ALDH1A1EPHX1 | |
| SCHEMBL3734489 | 0.91 | NAAA (0.65) | NAAAASAH1ALDH1A1CTSLGAA | |
| SCHEMBL4074285 | 0.91 | NAAA (0.65) | NAAAASAH1ALDH1A1CTSLGAA | |
| SCHEMBL4084617 | 0.91 | NAAA (0.65) | NAAAASAH1ALDH1A1CTSLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020834-A1 | Method for preparation of sulphostin and its analogue or intermediates thereof | SOST, PTMS, FGF23 | NAAA 3150/4885ASAH1 2012/4885ALDH1A1 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.